Skip to content

Stoke Therapeutics

US · STOK #2942 by market cap Listed 2019
26.81 -0.12 -0.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 26.37 -2.08%
After-hours 27.40 +2.20%
33.4622.5026.812026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on STOK?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -9.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 16.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Operating margin -11.2% Better than 14%
Net margin -3.7% Better than 21%
Return on equity -2.4% Better than 25%
Return on invested capital -2.3% Better than 25%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -17.0% Better than 36%
6-month return -8.6% Better than 42%
12-month return (ex latest month) -14.7% Better than 19%
Distance below 52-week high 33.3% Better than 37%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.3x Better than 87%
Debt to assets 0.7% Better than 94%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 80.3% Better than 78%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +0.49%
1M +0.75%
3M -14.62%
6M -11.50%
YTD -15.53%
1Y -4.01%
3Y +542.93%
5Y -3.56%

Key statistics

Price & volume

Prev close
26.93
Open
26.39
Day range
25.94 - 27.78
Avg price
26.90
Volume
615.75K
Turnover
16.57M
Amplitude
6.83%
52-week range
22.05 - 40.22

Valuation

P/E
-223.42
P/E (TTM)
-7.09
P/B
4.97
EPS
-0.12
Net profit
-7.85M
Net assets
352.61M

Share structure

Market cap
1.75B
Float cap
1.34B
Shares out
65.41M
Float shares
49.92M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-06-19
52-week range 26% of range
22.05 40.22

33.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-17.31M net over the window

Short interest

Shares short
10.72M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Stoke Therapeutics (STOK)?

Stoke Therapeutics last traded at 26.81. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Stoke Therapeutics's market cap?

About 1.75B.

What is the P/E ratio of Stoke Therapeutics?

The trailing twelve-month P/E is -7.09. The Valuation tab shows it against the stock's own five-year range.

Does Stoke Therapeutics pay a dividend?

Stoke Therapeutics does not currently pay a regular dividend.

Is Stoke Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 48.33, which implies 80.3% upside from the current price. This is not investment advice.

What is Stoke Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Stoke Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Stoke Therapeutics discussion 0 comments

Add a comment